Key statistics
On Friday, Apellis Pharmaceuticals Inc (APLS:NSQ) closed at 23.49, -23.05% below its 52-week high of 30.53, set on Feb 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.68 |
|---|---|
| High | 23.58 |
| Low | 22.57 |
| Bid | 23.30 |
| Offer | 25.50 |
| Previous close | 22.56 |
| Average volume | 4.39m |
|---|---|
| Shares outstanding | 126.53m |
| Free float | 108.91m |
| P/E (TTM) | 79.10 |
| Market cap | 2.97bn USD |
| EPS (TTM) | 0.297 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
- Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
- Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
- New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
- Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
More ▼
